Acute Myeloid Leukemia Clinical Trial
Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders
Summary
Aim of the study is to analyze the expression of genes and sequences encoding the human mammalian diaphanous (mDia) related formin proteins to test the hypothesis that defects in the mDia expression or function might drive the pathophysiology of myelodysplastic syndrome, acute myeloid leukemia and other myeloproliferative diseases.
Full Description
Leukocytes and myeloid lineage cells from these specimens will be assayed for expression of DRF genes using standard molecular biological approaches to measure mRNA levels. Extracted DNA will be analyzed for mutations that affect expressions or function using direct sequencing techniques.
Alternatively, expression of DRF gene products (mDia proteins) will be assessed using specific antibodies and flow cytometry. Molecular findings resulting from these assays will be correlated with clinical information recorded in specimen logbook.
Eligibility Criteria
Inclusion Criteria:
18 and over
Male
Female
Diagnosed with MDS, MPD and AML
Exclusion Criteria:
Under the age of 18
Received bone marrow transplant
Control Group Criteria:
inclusion:
healthy men and women
≥ 55 years of age
exclusion:
history of hematological condition
history of cancer
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Grand Rapids Michigan, 49503, United States
Grand Rapids Michigan, 49503, United States
How clear is this clinincal trial information?